Want to see AMPH full AI Analyst Report?
AMPH Stock Chart & Stats
$18.72
-$0.15(-0.79%)
At close: 4:00 PM EDT
$18.72
-$0.15(-0.79%)
Day’s Range― - ―
52-Week Range$16.65 - $31.26
Previous Close$18.72
Volume445.68K
Average Volume (3M)514.01K
Market Cap
$887.34M
Enterprise Value$1.29K
Total Cash (Recent Filing)$290.12M
Total Debt (Recent Filing)$688.32M
Price to Earnings (P/E)12.0
Beta0.77
Next Earnings
Nov 09, 2026EPS Estimate
0.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.74
Shares Outstanding42,537,945
10 Day Avg. Volume439,376
30 Day Avg. Volume514,011
Financial Highlights & Ratios
PEG Ratio-0.35
Price to Book (P/B)1.59
Price to Sales (P/S)1.74
P/FCF Ratio10.33
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$22.17Price Target Upside18.41% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)2.86
Revenue Forecast (FY)$745.16M
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationConsistent TTM operating cash flow and high free cash flow provide durable financial flexibility. This supports continued R&D and manufacturing investments, share repurchases, and the ability to absorb remediation costs without immediate liquidity stress, improving resilience over the next several quarters.
Manufacturing Capability & Vertical IntegrationDemonstrated ability to take complex generics from development to commercial production and ongoing U.S. automation and capacity investments strengthen competitive positioning. Vertical integration and domestic capacity reduce supply risk, aid margin sustainability, and support faster scale for future launches.
BAQSIMI Franchise And Pipeline ProgressBAQSIMI prescription growth and the $100M milestone show commercial traction and significant near-term cash upside. Combined with advancing the insulin aspart biosimilar toward potential 2027 commercialization, this diversifies revenue mix and creates durable medium-term growth optionality.
Bears Say
Regulatory Risk At IMSAn FDA warning letter at a subsidiary that represents roughly one‑third of sales is a structural operational risk. Ongoing remediation and redirected capex increase costs, may constrain batch releases, and can impair customer supply reliability, creating sustained headwinds until fully resolved.
Margin Compression And VolatilityMaterial decline from prior peak margins indicates weaker pricing power, mix shifts to lower‑margin products, and higher costs. Persistent margin compression reduces cushion for investments and remediation, increases sensitivity to revenue dips, and makes earnings less predictable over the medium term.
Product Declines & Pricing PressureSharp declines in specific products and ASP pressure from rebates and 340B dynamics highlight vulnerability to competition and payer dynamics. Coupled with rising SG&A and G&A, these trends can compress operating leverage and slow durable top‑line recovery across the portfolio.
Amphastar Pharmaceuticals News
AMPH FAQ
What was Amphastar Pharmaceuticals Inc’s price range in the past 12 months?
Amphastar Pharmaceuticals Inc lowest stock price was $16.64 and its highest was $31.26 in the past 12 months.
What is Amphastar Pharmaceuticals Inc’s market cap?
Amphastar Pharmaceuticals Inc’s market cap is $887.34M.
When is Amphastar Pharmaceuticals Inc’s upcoming earnings report date?
Amphastar Pharmaceuticals Inc’s upcoming earnings report date is Nov 09, 2026 which is in 82 days.
How were Amphastar Pharmaceuticals Inc’s earnings last quarter?
Amphastar Pharmaceuticals Inc released its earnings results on Aug 06, 2026. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.29.
Is Amphastar Pharmaceuticals Inc overvalued?
According to Wall Street analysts Amphastar Pharmaceuticals Inc’s price is currently Undervalued.
Does Amphastar Pharmaceuticals Inc pay dividends?
Amphastar Pharmaceuticals Inc pays a Annually dividend of $0.3 which represents an annual dividend yield of N/A. See more information on Amphastar Pharmaceuticals Inc dividends here
What is Amphastar Pharmaceuticals Inc’s EPS estimate?
Amphastar Pharmaceuticals Inc’s EPS estimate is 0.86.
How many shares outstanding does Amphastar Pharmaceuticals Inc have?
Amphastar Pharmaceuticals Inc has 42,537,945 shares outstanding.
What happened to Amphastar Pharmaceuticals Inc’s price movement after its last earnings report?
Amphastar Pharmaceuticals Inc reported an EPS of $0.91 in its last earnings report, beating expectations of $0.62. Following the earnings report the stock price went up 4.897%.
Which hedge fund is a major shareholder of Amphastar Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in AMPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amphastar Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$22.17 (18.41% Upside)
$22.17 (18.41% Upside)
Blogger Sentiment
Neutral
AMPH Sentiment 50%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Decreased
By 292.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $161.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 11.5%
Last 30 Days ▲ 11.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.26%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
7.95%
Trailing 12-Months
Company Description
Amphastar Pharmaceuticals Inc
Amphastar Pharmaceuticals, Inc. (AMPH) is a specialty pharmaceutical company that develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products, with operations spanning active pharmaceutical ingredient (API) manufacturing and finished-dose drug production. The company focuses on complex and technically challenging dosage forms and supplies products primarily to hospitals, clinics, and retail/wholesale pharmaceutical channels in the U.S. and select international markets.
AMPH Company Deck
AMPH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a mix of positive operational execution and material near-term challenges. Key positives include 5% revenue growth to $183.9M, gross margin expansion to 51%, successful new product launches (ipratropium bromide and other recent launches), strong BAQSIMI prescription growth (up ~17%) and a contract-year BAQSIMI milestone triggering a $100M payment in Q3. The company generated meaningful operating cash flow (~$51.3M) and repurchased ~$45M of stock, and advanced its development pipeline toward potential 2027 commercialization of the insulin aspart biosimilar and early-stage proprietary programs. On the negative side, the IMS FDA warning letter and related remediation will add $2–3M per quarter in expenses and could slow IMS sales and batch releases; glucagon sales declined sharply (-42% YoY) and several operating expense categories rose substantially (SG&A and G&A +30%). Management still maintained full-year sales guidance and emphasized diversification and U.S. manufacturing investments. Balancing the operational progress, financial improvements, and the notable regulatory and cost headwinds, the overall tone is cautiously constructive.View all AMPH earnings summariesAMPH Stock 12 Month Forecast
Average Price Target
$22.17
▲(18.41% Upside)
Technical Analysis
Viatris
―
Pacira Pharmaceuticals
―
Teva Pharmaceutical
―
ANI Pharmaceuticals
―
Amneal Pharmaceuticals
―
Ownership Overview
28.21% Insiders
21.72% Mutual Funds
9.70% Other Institutional Investors
15.14% Public Companies and
Individual Investors